BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Koom WS, Seong J, Kim YB, Pyun HO, Song SY. CA 19-9 as a predictor for response and survival in advanced pancreatic cancer patients treated with chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2009;73:1148-1154. [PMID: 18760544 DOI: 10.1016/j.ijrobp.2008.06.1483] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 2.1] [Reference Citation Analysis]
Number Citing Articles
1 Bilici A. Prognostic factors related with survival in patients with pancreatic adenocarcinoma. World J Gastroenterol 2014; 20(31): 10802-10812 [PMID: 25152583 DOI: 10.3748/wjg.v20.i31.10802] [Cited by in CrossRef: 64] [Cited by in F6Publishing: 62] [Article Influence: 8.0] [Reference Citation Analysis]
2 Yang GY, Malik NK, Chandrasekhar R, Ma WW, Flaherty L, Iyer R, Kuvshinoff B, Gibbs J, Wilding G, Warren G, May KS. Change in CA 19-9 levels after chemoradiotherapy predicts survival in patients with locally advanced unresectable pancreatic cancer. J Gastrointest Oncol 2013;4:361-9. [PMID: 24294507 DOI: 10.3978/j.issn.2078-6891.2013.045] [Cited by in F6Publishing: 15] [Reference Citation Analysis]
3 Altwegg R, Ychou M, Guillaumon V, Thezenas S, Senesse P, Flori N, Mazard T, Caillo L, Faure S, Samalin E, Assenat E. Second-line therapy for gemcitabine-pretreated advanced or metastatic pancreatic cancer. World J Gastroenterol 2012; 18(12): 1357-1364 [PMID: 22493549 DOI: 10.3748/wjg.v18.i12.1357] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
4 Kim YJ, Koh HK, Chie EK, Oh DY, Bang YJ, Nam EM, Kim K. Change in carbohydrate antigen 19-9 level as a prognostic marker of overall survival in locally advanced pancreatic cancer treated with concurrent chemoradiotherapy. Int J Clin Oncol 2017;22:1069-75. [PMID: 28477059 DOI: 10.1007/s10147-017-1129-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
5 Awad S, Alkashash AM, Amin M, Baker SJ, Rose JB. Biochemical Predictors of Response to Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma. Front Oncol 2020;10:620. [PMID: 32477933 DOI: 10.3389/fonc.2020.00620] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
6 Yoo T, Lee WJ, Woo SM, Kim TH, Han SS, Park SJ, Moon SH, Shin KH, Kim SS, Hong EK. Pretreatment carbohydrate antigen 19-9 level indicates tumor response, early distant metastasis, overall survival, and therapeutic selection in localized and unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys. 2011;81:e623-e630. [PMID: 21600705 DOI: 10.1016/j.ijrobp.2011.02.063] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
7 Chen H, Tu H, Meng Z, Chen Z, Wang P, Liu L. K-ras mutational status predicts poor prognosis in unresectable pancreatic cancer. European Journal of Surgical Oncology (EJSO) 2010;36:657-62. [DOI: 10.1016/j.ejso.2010.05.014] [Cited by in Crossref: 81] [Cited by in F6Publishing: 80] [Article Influence: 6.8] [Reference Citation Analysis]
8 Lee JH, Kang CM, Bang SM, Choi JY, Seong JS, Hwang HK, Choi SH, Lee WJ. The Role of Neoadjuvant Chemoradiation Therapy in Patients With Borderline Resectable Pancreatic Cancer With Isolated Venous Vascular Involvement. Medicine (Baltimore) 2015;94:e1233. [PMID: 26252282 DOI: 10.1097/MD.0000000000001233] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
9 Vainshtein JM, Schipper M, Zalupski MM, Lawrence TS, Abrams R, Francis IR, Khan G, Leslie W, Ben-Josef E. Prognostic significance of carbohydrate antigen 19-9 in unresectable locally advanced pancreatic cancer treated with dose-escalated intensity modulated radiation therapy and concurrent full-dose gemcitabine: analysis of a prospective phase 1/2 dose escalation study. Int J Radiat Oncol Biol Phys 2013;86:96-101. [PMID: 23265573 DOI: 10.1016/j.ijrobp.2012.11.020] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
10 Kim HJ, Lee WJ, Kang CM, Hwang HK, Bang SM, Song SY, Seong J. Risk Factors Associated with Loco-Regional Failure after Surgical Resection in Patients with Resectable Pancreatic Cancer. PLoS One 2016;11:e0157196. [PMID: 27332708 DOI: 10.1371/journal.pone.0157196] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
11 van der Sijde F, Vietsch EE, Mustafa DAM, Besselink MG, Groot Koerkamp B, van Eijck CHJ. Circulating Biomarkers for Prediction of Objective Response to Chemotherapy in Pancreatic Cancer Patients. Cancers (Basel) 2019;11:E93. [PMID: 30650521 DOI: 10.3390/cancers11010093] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
12 Hsu CP, Lee LY, Hsu JT, Hsu YP, Wu YT, Wang SY, Yeh CN, Chen TC, Hwang TL. CD44 Predicts Early Recurrence in Pancreatic Cancer Patients Undergoing Radical Surgery. In Vivo 2018;32:1533-40. [PMID: 30348713 DOI: 10.21873/invivo.11411] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
13 Zeeshan MS, Ramzan Z. Current controversies and advances in the management of pancreatic adenocarcinoma. World J Gastrointest Oncol 2021; 13(6): 472-494 [PMID: 34163568 DOI: 10.4251/wjgo.v13.i6.472] [Reference Citation Analysis]
14 Zschaeck S, Blümke B, Wust P, Kaul D, Bahra M, Riess H, Klein F, Sinn M, Pelzer U, Budach V, Ghadjar P. Dose-escalated radiotherapy for unresectable or locally recurrent pancreatic cancer: Dose volume analysis, toxicity and outcome of 28 consecutive patients. PLoS One 2017;12:e0186341. [PMID: 29023527 DOI: 10.1371/journal.pone.0186341] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
15 Ogura T, Yamao K, Hara K, Mizuno N, Hijioka S, Imaoka H, Sawaki A, Niwa Y, Tajika M, Kondo S. Prognostic value of K-ras mutation status and subtypes in endoscopic ultrasound-guided fine-needle aspiration specimens from patients with unresectable pancreatic cancer. J Gastroenterol. 2013;48:640-646. [PMID: 22983505 DOI: 10.1007/s00535-012-0664-2] [Cited by in Crossref: 61] [Cited by in F6Publishing: 56] [Article Influence: 6.1] [Reference Citation Analysis]
16 Diaz CL, Cinar P, Hwang J, Ko AH, Tempero MA. CA 19-9 Response: A Surrogate to Predict Survival in Patients With Metastatic Pancreatic Adenocarcinoma. American Journal of Clinical Oncology 2019;42:898-902. [DOI: 10.1097/coc.0000000000000620] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
17 Mayahara H, Ito Y, Morizane C, Ueno H, Okusaka T, Kondo S, Murakami N, Morota M, Sumi M, Itami J. Salvage chemoradiotherapy after primary chemotherapy for locally advanced pancreatic cancer: a single-institution retrospective analysis. BMC Cancer 2012;12:609. [PMID: 23256481 DOI: 10.1186/1471-2407-12-609] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
18 Lee KJ, Yoon HI, Chung MJ, Park JY, Bang S, Park SW, Seong JS, Song SY. A Comparison of Gastrointestinal Toxicities between Intensity-Modulated Radiotherapy and Three-Dimensional Conformal Radiotherapy for Pancreatic Cancer. Gut Liver 2016;10:303-9. [PMID: 26470767 DOI: 10.5009/gnl15186] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
19 Kinny-Köster B, Habib JR, Wolfgang CL, He J, Javed AA. Favorable tumor biology in locally advanced pancreatic cancer-beyond CA19-9. J Gastrointest Oncol 2021;12:2484-94. [PMID: 34790409 DOI: 10.21037/jgo-20-426] [Reference Citation Analysis]
20 Choi SH, Park SW, Seong J. A nomogram for predicting survival of patients with locally advanced pancreatic cancer treated with chemoradiotherapy. Radiother Oncol 2018;129:340-6. [PMID: 30177371 DOI: 10.1016/j.radonc.2018.08.006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
21 Marlet J, Bernard M. Comparison of LUMIPULSE(®) G1200 With Kryptor and Modular E170 for the Measurement of Seven Tumor Markers. J Clin Lab Anal 2016;30:5-12. [PMID: 25283278 DOI: 10.1002/jcla.21802] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
22 Kang CM, Chung YE, Park JY, Sung JS, Hwang HK, Choi HJ, Kim H, Song SY, Lee WJ. Potential contribution of preoperative neoadjuvant concurrent chemoradiation therapy on margin-negative resection in borderline resectable pancreatic cancer. J Gastrointest Surg. 2012;16:509-517. [PMID: 22183861 DOI: 10.1007/s11605-011-1784-3] [Cited by in Crossref: 63] [Cited by in F6Publishing: 48] [Article Influence: 5.7] [Reference Citation Analysis]
23 Shultz DB, Chan C, Shaffer JL, Kunz PL, Koong AC, Chang DT. Postradiotherapy CA19-9 kinetics correlate with outcomes in patients with pancreatic adenocarcinoma. Pancreas 2014;43:777-83. [PMID: 24632549 DOI: 10.1097/MPA.0000000000000098] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
24 Al-Shamsi HO, Alzahrani M, Wolff RA. The clinical utility of normal range carbohydrate antigen 19-9 level as a surrogate marker in evaluating response to treatment in pancreatic cancer-a report of two cases. J Gastrointest Oncol 2016;7:E45-51. [PMID: 27284488 DOI: 10.21037/jgo.2016.01.05] [Cited by in Crossref: 20] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
25 Kang YM, Wang H, Li R, Pan G. Prognostic Role of Carbohydrate Antigen 19 to 9 in Predicting Survival of Patients With Pancreatic Cancer: A Meta-Analysis. Technol Cancer Res Treat 2021;20:15330338211043030. [PMID: 34617852 DOI: 10.1177/15330338211043030] [Reference Citation Analysis]
26 Ielpo B. The issue of how predict survival of patients affected by locally advanced pancreatic cancer. Ann Transl Med 2018;6:S128. [PMID: 30740449 DOI: 10.21037/atm.2018.12.41] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
27 Lee KJ, Yi SW, Chung MJ, Park SW, Song SY, Chung JB, Park JY. Serum CA 19-9 and CEA levels as a prognostic factor in pancreatic adenocarcinoma. Yonsei Med J. 2013;54:643-649. [PMID: 23549809 DOI: 10.3349/ymj.2013.54.3.643] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 5.3] [Reference Citation Analysis]
28 Woo SM, Lee WJ, Han S, Park S, Kim TH, Koh YH, Kim HB, Hong EK, Park J, Kim C. Capecitabine plus Cisplatin as First-Line Chemotherapy for Advanced Biliary Tract Cancer: A Retrospective Single-Center Study. Chemotherapy 2012;58:225-32. [DOI: 10.1159/000339499] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
29 Shultz DB, Pai J, Chiu W, Ng K, Hellendag MG, Heestand G, Chang DT, Tu D, Moore MJ, Parulekar WR, Koong AC. A Novel Biomarker Panel Examining Response to Gemcitabine with or without Erlotinib for Pancreatic Cancer Therapy in NCIC Clinical Trials Group PA.3. PLoS One 2016;11:e0147995. [PMID: 26808546 DOI: 10.1371/journal.pone.0147995] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
30 Zhou J, Fang CX, Shen J, Schipper MJ, Zalupski MM, Minter RM, Simeone DM, Hart D, Eagle T, Kimmel GW, Vainshtein J, Lawrence TS, Feng M. Definitive Chemoradiation With Full-dose Gemcitabine for Unresectable Pancreatic Cancer: Efficacy of Involved-Field Radiotherapy. Am J Clin Oncol 2017;40:517-22. [PMID: 26165418 DOI: 10.1097/COC.0000000000000200] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
31 Tanase CP, Neagu M, Albulescu R, Hinescu ME. Advances in pancreatic cancer detection. Adv Clin Chem. 2010;51:145-180. [PMID: 20857621 DOI: 10.1016/s0065-2423(10)51006-0] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]